IP Library Granted Patent US 9,556,249
Granted Patent B2
US 9,556,249 · App. 13/029,199 · Granted Jan 31, 2017

Neuregulin antagonists and use thereof in treating cancer

Inventors: Erica Jackson (San Francisco, CA); Eric Alejandro Sweet-Cordero (San Francisco, CA)
Assignees: Genentech, Inc.; The Board of Trustees of the Leland Stanford Junior University
C07K14/4756A61K31/7088A61K39/3955A61K45/06C07K14/71C12N15/1136A61K38/00C07K2319/30C12N2310/14C12N2310/531
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,556,249
App. No.
13/029,199
Granted
Jan 31, 2017
Kind
B2
Abstract

The invention provides neuregulin antagonists and methods of using the neuregulin antagonists in delaying the time to tumor recurrence or preventing resistance of cancer cells to treatment with a therapeutic agent.

Claims (15)

1. A method of increasing time to tumor recurrence in a cancer patient whose cancer was previously treated comprising administering to the patient an effective amount of a neuregulin antagonist and a chemotherapeutic, wherein the neuregulin antagonist is an anti-NRG1 antibody and wherein the chemotherapeutic agent is selected from the group consisting of paclitaxel, cisplatin, and a combination of paclitaxel and cisplatin and further wherein the cancer is selected from the group consisting of non-small cell lung cancer, breast cancer, ovarian cancer, head and neck cancer, cervical cancer, bladder cancer , oesophageal cancer, prostate cancer, and colorectal cancer.

2. The method of claim 1 , wherein the increase in time to tumor recurrence is at least 1.25 fold greater than the time to recurrence in the absence of the neuregulin antagonist.

3. The method of claim 1 , wherein the increase in time to tumor recurrence is at least 1.50 fold greater than the time to recurrence in the absence of the neuregulin antagonist.

4. The method of claim 1 , wherein the chemotherapeutic agent is paclitaxel.

5. The method of claim 1 , wherein the chemotherapeutic agent is cisplatin.

6. The method of claim 1 , wherein the chemotherapeutic agent is a combination of paclitaxel and cisplatin.

7. The method of claim 1 , wherein the cancer is non-small cell lung cancer.

8. The method of claim 1 , wherein the cancer is breast cancer.

9. The method of claim 1 , wherein the cancer is ovarian cancer.

10. The method of claim 1 , wherein the cancer is head and neck cancer.

11. The method of claim 1 , wherein the cancer is cervical cancer.

12. The method of claim 1 , wherein the cancer is bladder cancer.

13. The method of claim 1 , wherein the cancer oesophageal cancer.

14. The method of claim 1 , wherein the cancer is prostate cancer.

15. The method of claim 1 , wherein the cancer is colorectal cancer.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 17, 2012
From: JACKSON, ERICA
To: GENENTECH, INC.
Reel/Frame 028568/0627 →
Continuity (2)
Provisional Application 61305878 · Feb 18, 2010
Related Publication 20110229493A1 · Sep 22, 2011